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ABSTRACT
Purpose: Tracheal occlusion (TO) reverses pulmonary hypoplasia (PH) in congenital
diaphragmatic hernia (CDH), but its effect on epithelial-mesenchymal transition (EMT) in lung
development remains poorly understood. The purpose of this study was to a) confirm the CDH
rabbit model produced PH which was reversed by TO and b) determine the effects of CDH +/- TO
on EMT pathways.
Methods: CDH was created at 23 days, TO at 28 days and lung collection at 31 days gestation in
fetal rabbits. Lung body weight ratio (LBWR), mean terminal bronchiole density (MTBD), and
expression of mRNA and micro-RNA was determined.
Results: Fifteen CDH, 15 CDH+TO, 6 sham CDH, and 15 controls were included in the study.
LBWR was low in CDH while CDH+TO was similar to controls. MTBD was higher in CDH
fetuses and restored to control levels in CDH+TO. miR-33 and MKI67 were increased following
TO, while Lgl1 was decreased in CDH+TO.
Conclusion: TO reversed PH and stimulated early Wnt signaling in CDH fetal rabbits.

KEYWORDS: Congenital diaphragmatic hernia (CDH), tracheal occlusion (TO), epithelialmesenchymal transition (EMT), lung development, Wnt signaling, TGF- signaling, retinoic acid
(RA) signaling, micro-RNA (miRNA)
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CHAPTER 1: INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a birth defect that occurs in every 2000-4000 live
births [1,2]. CDH occurs when a failure in the fusion of the diaphragm results in a diaphragmatic
defect (DD) that allows intra-abdominal contents to herniate into the chest cavity, compressing the
lung and inhibiting normal lung development [3]. Several theories exist to explain the
pathophysiology of CDH including: abnormal phrenic nerve innervation, improper myotube
formation, failure of pleuroperitoneal canal closure, and improper pleuroperitoneal fold
development [3]. The dual-hit hypothesis suggests that CDH causes lung hypoplasia with two
insults – the first affects both lungs prior to the completion of diaphragm development, and the
second results from compression of the ipsilateral lung by intra-abdominal organs herniating into
the chest [4]. CDH is detrimental to key components of lung development, including retinoic acid
(RA), transforming growth factor-β (TGF-), and wingless-type MMTV integration site (Wnt)
signaling pathways, which normally stimulate epithelial-mesenchymal transition (EMT) and lead
to branching morphogenesis [3]. Clinically, CDH results in lung hypoplasia and pulmonary
hypertension [3]. Lung hypoplasia results in decreased alveolar surface and vasculature causing
hypoxia and hypercarbia, leading to pulmonary vasoconstriction, worsening pulmonary
hypertension, right to left shunting, and a cycle of respiratory compromise [1,3]. Although CDH
is also associated with various anomalies such as trisomy 13 and 18, congenital syndromes, and
cardiac malformations, most fetuses that survive to term have isolated CDH [1]. The majority of
CDH in humans, around 70%, are posterolateral Bochdalek hernias. Approximately 27% of CDH
cases are anterior Morgagni hernias, and 2-3% are central hernias.
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Over the past 25 years, the overall survival of all CDH babies in Canada has risen from 50%
to 80% [5]. There have been great advances in the medical management of patients with CDH
that account for this 30% increase in survival. These medical advances include extracorporeal
membrane oxygenation (ECMO), high frequency oscillating ventilation (HFOV), inhaled nitric
oxide (iNO), and gentle ventilation with permissive hypercapnia [1]. These management options
treat the sequelae of CDH rather than the condition itself [6]. This has led to improved survival of
more severe cases of CDH and therefore results in more long-term complications in these patients
including failure to thrive, gastroesophageal reflux, deafness, and neurological complications
[1,7]. However, over the last decade, the mortality rate has remained stagnant at 20% [1,7].

The significant morbidity and mortality associated with CDH due to respiratory compromise
led to the recognition of a need for fetal treatment that would allow lung growth and minimize
lung hypoplasia [1]. In the 1980s, Harrison et al were the first to successfully repair CDH in utero
and began a nonrandomized prospective trial comparing fetal CDH repair to medical management.
The trial revealed that CDH repair was associated with premature rupture of membranes,
premature delivery, and fetal death while showing no advantage in survival or length of stay
compared to medical management [1,8–11]. The trial was therefore stopped early.

The concept of fetal tracheal occlusion (TO) came from the observation that fetuses with
laryngeal atresia were born with hyperplastic lungs [1]. The mechanism of lung hyperplasia was
thought to be due to mechanical distention from increased lung fluid pressure as a result of tracheal
obstruction [1,12–14]. TO was first applied in the context of CDH in the early 1990s in the lamb
CDH model, where significant lung growth and reversal of pulmonary hypoplasia was noted
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following TO [1,15,16]. TO in humans has evolved from an open Ex-utero Intrapartum Treatment
(EXIT) technique to a minimally invasive procedure referred to as Fetal Endoluminal Tracheal
Occlusion (FETO) [1,17]. Despite these advances, FETO is still associated with risks of premature
rupture of membranes and premature delivery [17,18]. However, FETO does improve survival in
fetuses with severe CDH by 25%, and is therefore utilized in this high risk population of CDH
fetuses in a handful of centres across the world [17,18].

FETO also targets lung development on a molecular level. Human fetuses undergoing FETO
were found to have increased levels of miR-200b in their tracheal fluid following release of the
TO by balloon removal [19]. On the other hand, overexpression of miR-200b in hypoplastic CDH
lungs resulted in decreased TGF- signaling which normally stimulates EMT and branching
morphogenesis during fetal lung development [19]. Overall, research in human CDH fetuses is
uncommon due to the rarity of the condition, difficulty with obtaining samples, and also ethical
concerns. Animal models have therefore played a major role in CDH research and continue to be
utilized to this day.

Although advances have been made in both post-natal medical management and fetal
intervention for fetuses with CDH, morbidity and mortality risks secondary to lung complications
remain a significant concern for this population. Decades of research have been dedicated to the
study of CDH and TO in order to broaden our understanding of this birth defect and the mechanism
of a promising treatment. More recently, animal models have been utilized to explore potential
prenatal therapies that may be used to stimulate lung growth in CDH. The goal of such prenatal
therapy is to augment and ultimately replace an invasive procedure such as FETO to treat lung
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hypoplasia in CDH. The aim of this study was to replicate the rabbit model of CDH and to study
the effects of TO on anatomic, morphologic, and molecular markers of fetal lung development.
Identifying cell signaling markers that stimulate lung growth following TO could lead to potential
non-invasive prenatal molecular therapies that promote lung growth and prevent the respiratory
complications which are caused by CDH.
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CHAPTER 2: REVIEW OF LITERATURE
A. Fetal Lung Development
In humans, lung development begins at 4 weeks gestation as the anterior foregut separates into
the trachea, two lung buds, and the esophagus [20]. Lung development occurs in 5 stages:
embryonic, pseudoglandular, canalicular, saccular, and alveolar [21]. The pseudoglandular stage
occurs from 5-16 weeks of gestation and during this stage airway branching morphogenesis takes
place [20]. The canalicular stage occurs from 16-26 weeks of gestation, during which time terminal
bronchioles divide into respiratory bronchioles and alveolar ducts, and pulmonary vasculature
forms [20]. Epithelial sacs are formed during the saccular stage which occurs from 26-38 weeks
of gestation [20]. The final alveolar stage begins at 38 weeks of gestation and continues until
approximately 7 years of age in children. During the alveolar stage, the epithelial sacs form alveoli
through secondary septation [20].

The gestational period in rabbits is approximately 32 days [21–23]. The pseudoglandular stage
of lung development occupies 75% of the gestational period and lasts until day 24 of gestation
[21]. The canalicular phase occurs from 24-28 days gestation and the saccular stage from 27-30
days [21–23]. Similar to humans, the alveolar stage in rabbits begins in utero prior to delivery and
continues in the post-natal period [22–24]. It is important to note that in fetal rabbits there is some
overlap in gestational days for lung development as one stage transitions into the next.

B. Fetal Diaphragm Development
The diaphragm is the most essential skeletal muscle in mammals because it is required for
respiration [25]. In humans, diaphragm development begins at 4 weeks of gestation, approximately
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at the same time as lung development [20]. The diaphragm is composed of the dorsomedial crural
muscle, the ventrolateral costal muscle, and an amuscular central tendon [20]. The costal
diaphragm is thin and composed of myofibers that extend from the ribs to the central tendon [25].
The crural diaphragm is thicker, attaches posteriorly to the vertebrae and surrounds the esophagus
and aorta [25]. The central tendon is composed of connective tissue which holds the diaphragm
muscles together and also attaches to the liver via the falciform and coronary ligaments [25].
During fetal development, the diaphragm originates from three embryologic sources – the septum
transversum, pleuroperitoneal folds, and somites [25]. The septum transversum is a mesodermal
sheet that forms a barrier between the chest and abdominal cavities and forms a scaffold for further
diaphragm development [20,25]. The diaphragm muscle cells originate from somites which
migrate as pleuroperitoneal folds [20]. The pleuroperitoneal folds, also known as the posthepatic
mesenchymal plate, is a transient embryonic structure that lies on either side of the esophagus [25].
The diaphragm is innervated by the phrenic nerves which migrate from the neural tube originating
from cervical nerves 3, 4 and 5 [25].

Diaphragm development in rabbits occurs throughout the gestational period with a rapid
progression during the last third of gestation and is fully complete one week post-partum [26]. At
20 days of gestation, early myogenesis of the diaphragm occurs with fusion of myoblasts to form
myotubes [26]. Developing motor plates are observed at 22 days gestation, while connective tissue
sheaths and differentiation of muscle fibres occurs at 25 days gestation [26]. Diaphragmatic muscle
fibres form myotendinous junctions at 30 days gestation, and by one week post-partum the muscle
fibres of the diaphragm are fully differentiated and development of the diaphragm is complete
[26].
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C. Pathophysiology of CDH
The dual-hit hypothesis explains the pathophysiology of lung hypoplasia in CDH based on
research performed using the nitrofen-induced CDH rodent model, which showed that both
ipsilateral and contralateral lungs are hypoplastic and lung development is impaired before the
closure of the diaphragm [4]. In the dual-hit hypothesis, the first hit, or insult, affects both lungs
and occurs prior to diaphragm formation as a result of environmental and genetic factors [4]. The
second insult occurs following diaphragm development as a result of herniated intra-abdominal
contents in the chest which compresses the ipsilateral lung and inhibits fetal breathing [4].
According to this hypothesis, lung growth into the pleuroperitoneal canal is disturbed and inhibits
the growth of the posthepatic mesenchymal plate, which is the main origin of the diaphragm [4].
This theory therefore suggests that the diaphragmatic defect occurs because of abnormal
development of the adjacent lung [3,4].

Several other theories also exist with regards to the pathophysiology of the diaphragmatic
hernia itself. One theory is that the diaphragm does not fully develop properly due to abnormalities
of phrenic nerve innervation [3,27]. Another theory suggests that a diaphragmatic defect occurs
due to improper myotube formation which causes a weakness in the diaphragmatic muscle and
results in rupture due to pressure from intra-abdominal organs [3]. Yet another theory proposes
that CDH develops from the failure of pleuroperitoneal canal closure during the 10th week of
gestation in humans when intestines return to the abdominal cavity and enter the pleuroperitoneal
canal thus blocking the closure of the canal and forming a diaphragmatic hernia [3,28]. Lastly,
there is also a theory that suggests that CDH occurs as a result of abnormal pleuroperitoneal fold
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formation which then does not properly differentiate into the diaphragm as it would under normal
conditions [3,27].

D. Animal Models of CDH
Three types of CDH animal models exist – genetic, pharmacologic, and surgical. Genetic
models of CDH are primarily in rodent models with knockout genes [6,7]. This model is perhaps
the least popular because the majority of CDH cases in humans are not associated with genetic
defects and so the genetic model of CDH is the least applicable to the human condition [6,7]. The
pharmacologic model involves the use of herbicide 2,4-dichloro-phenyl-p-nitrophenylether
(nitrofen) in rodents and has been primarily used to study the pathophysiology of CDH. The
surgical model on the other hand, has been used in sheep and rabbits, and has proven to be more
useful in the study of CDH treatments and interventions.

Nitrofen is a teratogenic herbicide that was first used to explore its diaphragmatic defect
inducing effects in fetal rodents in the 1980s by Iritani [3,29]. Typically, 100 mg of nitrofen is
dissolved in 1 mL olive oil and administered on day 9 of gestation to induce CDH in rodents [4].
Nitrofen administration induces a right or left-sided diaphragmatic defect in 70-80% of fetuses and
causes lung hypoplasia in 100% of fetuses [3,6,30,31]. Advantages of the nitrofen-induced CDH
rodent model include inexpensive cost and ease of use [3,6]. However, although nitrofen induces
a diaphragmatic defect during early stages of lung development similar to humans, the use of a
teratogen to induce this defect is concerning since there is no known teratogen associated CDH in
humans [3]. Nitrofen targets the retinoic acid (RA) signaling pathway and inhibits retinal
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dehydrogenase [3,6]. Infants with CDH were found to have 50% less plasma retinol and retinol
binding protein. Therefore, the RA signaling pathway may be involved in the origin of CDH [3].

The surgical model of CDH has been utilized in exploring treatments and innovative therapies
in CDH [3,6]. This model has been utilized in sheep and rabbits [3,6]. The first surgical model of
CDH was developed using fetal lambs by Delorimier in the 1960s [3,6,32]. The diaphragmatic
defect was created surgically at 72-75 days of gestation, which corresponds with the canalicular
phase of lung development, with term being 145-149 days of gestation. In the early 1990s, the
surgical model of CDH was developed in fetal rabbits by Fauza et al [33]. There were many
advantages identified in using rabbits instead of sheep – lower cost, shorter gestational period of
32 days, and similar lung physiology to humans. In the rabbit model, the diaphragmatic defect is
created on gestational day 23, which is also during the pseudoglandular phase of lung development
[6]. The lung physiology is more similar to humans compared to other models because in rabbits
alveolarization begins prior to birth and completes in the post-natal period, whereas in sheep,
alveolarization is nearly complete at birth, and in rodents alveolarization begins in the post-natal
period [24].

The surgical model of CDH has been used to study the effects of TO on lung development.
Standard measures of lung growth and development include lung body weight ratio (LBWR) and
mean terminal bronchiole density (MTBD). LBWR, the ratio of fetal lung weight over fetal body
weight, is a gross anatomic measurement of lung growth and is commonly used to identify lung
hypoplasia in CDH research [22,24]. MTBD is a morphologic measure of the number of mean
terminal bronchioles per non-overlapping high powered field on microscopy [22]. MTBD is
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inversely proportional to the number of alveoli and is therefore used as a marker of lung hypoplasia
in CDH [22]. Increased MTBD means that there are few alveoli and that the lung is
underdeveloped and hypoplastic. On the other hand, decreased MTBD means increased number
of alveoli in a normally developed lung. Animal studies have confirmed that TO increases LBWR
and decreases MTBD in CDH fetuses, thus reversing lung hypoplasia. However, the molecular
mechanism of TO and its effect on lung development pathways are not fully understood.

E. EMT in Lung Development and the Wnt Signaling Pathway
EMT is a fundamental developmental process where epithelial cells transform into
mesenchymal-like cells [34]. This process occurs during embryologic development, gastrulation,
and tissue repair [34]. During fetal lung development, several cell signaling pathways stimulate
EMT including RA, TGF-, and Wnt signaling (Figure 1). Wnt signaling is essential in lung
development and stimulates EMT which leads to lung-branching morphogenesis [34]. Wnt
signaling activates several intracellular pathways that regulate maintenance, self-renewal and
differentiation of mammalian stem cells [35,36]. Wnt signaling is essential during early
development to regulate body axis formation, organogenesis, and cell migration in vertebrates
[36].
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Figure 1: Epithelial-Mesenchymal Transition (EMT) in Lung Development. EMT is targeted by several cell
signaling pathways including Wnt, TGF-, and RA.

Wnt is a large family of cysteine-rich signaling molecules that are vertebrate homologues of
Drosophila wingless [35]. The Wnt pathway was first discovered 30 years ago with the discovery
of a proto-oncogene named Int-1, a homolog of Drosophila wingless that controls segment polarity
in larvae [36]. Int-1 led to malignant transformation of mouse mammary tissue when inserted in
the Mouse Mammary Tumor Virus (MMTV) [36]. The gene was therefore named Wnt1, winglesstype MMTV integration site family member 1 [36].

Nineteen Wnt ligands have been identified in vertebrates [35–37]. Their classification is based
on amino acid sequence and not their functional properties [36]. Common structural features of
Wnt proteins include a signal sequence for secretion, several highly charged amino acid residues,
and multiple glycosylation sites [36]. Receptors of Wnt ligands include members of seven-pass
transmembrane proteins Frizzleds (FZDs), low density lipoprotein receptor-related protein (LRP)
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co-receptors, and retinoic acid receptor related orphan receptor (ROR) and receptor-like tyrosine
kinase (RYK) families [35,36].

Wnt pathways can be categorized as canonical and non-canonical, defined by their requirement
or independence of intracellular -catenin, respectively [35,36,38]. Wnt ligands elicit canonical or
noncanonical response dependent on cell type, environment, and receptor type [36]. The Wnt
signaling pathway is complex and dynamic [36]. When Wnt ligands bind to receptors and coreceptors on the cell surface, both -catenin dependent and independent cascades are set in motion
which can reinforce or oppose each other [36].

Canonical Wnt signaling controls cell proliferation, differentiation, migration, cell fate
specification and stem cell renewal (Figure 2) [35,38]. The canonical Wnt pathway is mediated by
stabilization of -catenin [35,38]. In the absence of Wnt ligands, -catenin is phosphorylated,
ubiquinated, and degraded [35]. When Wnt ligands bind to receptors, the seven transmembrane
FZD receptor and LRP co-receptor 5/6, they trigger intracellular responses that lead to inhibition
of -catenin phosphorylation [35,36]. The stabilized -catenin accumulates and translocates to the
nucleus where it interacts with the lymphoid enhancer binding factor 1 (LEF)/ transcription factor
family (TCF) complex to regulate target gene expression [35]. Wnt1, Wnt2, Wnt3, Wnt10b are
canonical Wnt ligands [36,39].
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Figure 2: The Role of Wnt Signaling in Lung Development. Wnt signaling stimulates cellular proliferation,
differentiation, lineage specification, and branching morphogenesis during fetal lung development.

Non-canonical Wnt signaling plays a role in cell migration, cell polarity and stem cell
maintenance [35]. Non-canonical Wnt signaling regulates and represses canonical Wnt activity
[35].

Non-canonical

signaling

cascades

are

subdivided

into

several

Wnt/Ca2+,

Wnt/Prolylcarboxypeptidase (PCP) and Dishevelled (DVL)-c-Jun N-terminal kinase (JNK)
pathways [35,36]. Wnt4, Wnt5a, Wnt5b, Wnt7a, Wnt 11, and Wnt16 are -catenin-independent
non-canonical Wnts [35,36].

Both canonical and non-canonical Wnt pathways are present in the lung. Wnt2, Wnt2b, Wnt3a,
Wnt5a, Wnt5b, Wnt7b, Wnt9a, and Wnt11 are expressed in lung tissue [36,37]. Airway structure
and function, including branching morphogenesis, are governed by epithelial mesenchymal
interactions that involve the Wnt/-catenin pathway (Figure 2) [37,38]. Deletion of Wnt/-catenin
results in abnormal epithelial, mesenchymal, and vascular development [38]. It also decreases
secondary and tertiary branching, leading to elongated bronchiolar tubules with poorly branched
and enlarged tips [38]. Wnt7b, for example, has been demonstrated to act on lung vascular smooth
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muscle cells (SMCs) through FZD1 and LRP5 [38]. Wnt7b is required for normal lung
mesenchymal proliferation in a narrow window of development before embryonic day 15 in mice
[37]. Wnt7b inactivation decreased airway branching, caused pulmonary hypoplasia, and
decreased lung muscular smooth muscle [37].

Wnt2 signaling occurs through the canonical Wnt/-catenin pathway [39]. Wnt2 and Wnt2b
specify lung progenitors within the anterior foregut during fetal development [39]. Wnt2/2b is
expressed in the lung mesenchyme and is essential in fetal lung development and specification
[39]. In the knockout mouse model, loss of Wnt2 leads to lung hypoplasia [39].

Wnt5a is the major Wnt ligand that activates the non-canonical Wnt pathway in the lung [35].
Wnt5a regulates branching morphogenesis during the pseudoglandular stage, promotes onset of
the saccular stage, and cell differentiation during lung maturation [35]. Non-canonical Wnt
signaling is important in pulmonary capillary patterning [35]. Deletion of Wnt5a results in
truncation of the trachea, overexpansion of the distal airways, and abnormal capillary formation
[35,40,41]. Non-canonical Wnt signaling is also critical for SMC function, extracellular matrix
(ECM) expression, and lung fibroblast formation [35,38].

The Wnt signaling pathway has been studied in the context of pulmonary hypoplasia in CDH.
Messenger RNA (mRNA) levels of Wnt7b and Wnt2 were significantly decreased during early
lung development in the nitrofen-induced congenital diaphragmatic hernia rat model [37]. Bone
morphogenetic protein 4 (BMP4), a downstream target of Wnt2 was downregulated in the ovine
model of CDH [42]. Furthermore, in a large pulmonary transcriptome analysis of fetal rabbits, Wnt
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inhibitor factor 1 (WIF1) was upregulated in CDH and downregulated following TO, while marker
of proliferation Ki-67 (MKI67) was upregulated in CDH+TO fetuses [43].

The RA signaling pathway also targets EMT during lung development [44]. Late gestation
lung protein 1 (Lgl1) is a downstream target of this pathway and remains prominent during
alveolarization of the lung [44]. Nitrofen inhibits retinal dehydrogenase of the RA signaling
pathway and downregulates Lgl1 expression in CDH fetuses. Lgl1 was found to downregulated in
the sheep model of CDH [42]. In the nitrofen-induced CDH rat model, Lgl1 was found to be
upregulated in CDH fetal rat lungs following RA prenatal therapy [45].

EMT in lung development is likewise regulated by the TGF- signaling pathway. This
pathway includes phosphodiesterases (PDEs) such as PDE4, that are altered in TGF- induced
EMT [46]. PDE5 is prominent during lung development and plays an important role in
angiogenesis, alveolarization, and maintaining normal fetal pulmonary hypertension [47].
Phosphodiesterase 5A (PDE5A) was previously reported to be increased in CDH fetal rabbit lungs,
and decreased following TO [43].

F. The role of microRNAs in Lung Development Pathways
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression through
post-transcriptional silencing of mRNAs [19,48,49]. miRNAs work by accelerating the
degradation of mRNAs or repressing translation, thereby negatively regulating the expression of
target genes (Figure 3) [50]. miRNAs are therefore important in signal transduction and function
as epigenetic regulators of cell signaling pathways [31,51]. miRNAs are essential for normal
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organogenesis during embryonic development [19,48,50]. To date, 1800 miRNAs have been
identified in humans [48].

Figure 3: The Role of MicroRNAs in Gene Expression. MicroRNAs are non-coding RNAs that negatively regulate
gene expression through the degradation of mRNA and the inhibition of translation to protein.

The study of miRNAs and their effect on cell signaling is a growing field, and several miRNAs
have been linked to lung development pathways. miR-17~92 cluster is involved in epithelial bud
morphogenesis and branching during early lung development by negatively regulating fibroblast
growth factor (FGF) signaling [52]. miR-124 regulates lung epithelial maturation and has been
linked to the Wnt/ catenin signaling pathway [53]. miR-142, which is highly expressed in
mesenchyme during early lung development, has also been found to interact with the Wnt/
catenin signaling pathway [54–56]. The overexpression of miR-375 was found to inhibit alveolar
epithelial differentiation by targeting the Wnt/ catenin signaling pathway [57,58].
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miRNAs have also been studied in CDH. There was increased expression of miR-375, an
inhibitor of Wnt/-catenin, in hypoplastic CDH lungs [50,58]. miR-18a, which promotes cell
proliferation and suppresses apoptosis, was found to be decreased in CDH [50,59]. Human fetus
CDH lungs had miR-200b and miR-10a overexpression compared to control lungs of human
fetuses from terminated pregnancies [19]. There was yet higher miR-200b expression in tracheal
fluid of fetuses that survived FETO at time of balloon removal compared to time of balloon
insertion [19]. miR-200b plays an important role in normal lung development by closely regulating
TGF- signaling [19]. TGF-2 expression was found to be decreased in CDH lungs [19]. This is
because miR-200b inhibits TGF-/SMAD signaling [19]. Therefore, TGF- activity enhances
miR-200 family expression as part of a negative feedback loop [19]. miR-200 expression increased
in CDH lungs and tracheal fluid samples of CDH patients responding to FETO, suggesting that
increases in miR-200 might result from an inherent increased TGF- expression in hypoplastic
lungs [19]. In a recent study, miR-200b knockout mice had abnormal lungs due to dysfunctional
surfactant, increased fibroblast-like cells, thicker mesenchyme between alveolar walls, disturbed
distal airway branching, and downregulation of epithelial cell differentiation [48]. miR-200b was
highly expressed during different stages of lung development and found to regulate distal airway
development by maintaining an epithelial cell phenotype [48].

Furthermore, the expression of several miRNAs were found to be altered in the nitrofeninduced CDH rodent model [50]. One study showed increased expression of 11 miRNAs and
decreased expression of 14 miRNAs in the CDH group [50]. Most notably, there was a marked
decrease in miR-33 in CDH rodent lungs [50]. miR-33 is a target of genes that regulate epithelialmesenchymal interactions, including PDGF and Wnt signaling pathways [50,60].
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G. Prenatal Therapy for CDH
CDH is a birth defect that continues to be associated with significant morbidity and risk of
death due to respiratory failure secondary to lung hypoplasia and pulmonary hypertension.
Currently FETO is the only treatment that reverses lung hypoplasia associated with CDH. The idea
of TO as a prenatal intervention for CDH came from an observation of lung hyperplasia in patients
born with laryngeal atresia [1]. The theory of TO was that by blocking the airway, fluid would
build up in the lung and cause it to grow [1,12–14]. Currently, FETO is being evaluated as a
therapy for left-sided severe and moderate CDH as part of a global randomized clinical trial [18].
The procedure can be offered outside the trial in cases of severe right-sided CDH [18]. In the most
recent literature, the FETO procedure takes a median amount of time of 10 minutes with a range
of 3 to 93 minutes. The procedure is typically performed under local anesthesia and optional
conscious sedation at 27-29 weeks gestation or at 30-32 weeks for moderate CDH cases [18].
Mothers are given tocolytics and antibiotics for 24 hours pre-procedure [18]. The mother is
positioned in supine position and external manipulation of the fetus is performed if necessary in
order to achieve an optimal fetal position with easy access to the fetal mouth [18]. The fetus is then
injected with analgesics and neuromuscular blockers intramuscularly [18]. A skin incision is made
in the mother’s abdomen and a 10 Fr trocar is inserted into the amniotic cavity under ultrasound
guidance and guided to be perpendicular to the fetal nose [18]. The fetoscope, a 1.3 mm fiber optic
endoscope, is then inserted into the fetus’ mouth and guided past the vocal cords and into the
trachea to the level of the carina [18]. A detachable latex balloon is then inflated and released
between the carina and vocal cords [18]. Following the procedure, patients are reassessed with
ultrasound every 1-2 weeks [18]. The balloon is scheduled to be removed at 34 weeks gestation or
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earlier if birth is impending [18]. The balloon is punctured with a needle under ultrasound guidance
and is expelled by the fetus spontaneously [18]. The reversal of TO before delivery is a key
maneuver because persistent TO until birth has been found to decrease the number of type II
pneumocytes resulting in decreased surfactant production and poorer outcomes [18].

Although prenatal TO for CDH was first established in the 1990s and is now performed using
a minimally invasive technique, FETO remains classified as an experimental procedure and is
performed in only a few centres in the world. Furthermore, this prenatal therapy is a surgical
procedure and is associated with risks including premature rupture of membranes and premature
delivery. For this reason, research efforts are focused on identifying less invasive prenatal therapy
options for the treatment of CDH associated pulmonary hypoplasia. Recent literature is promising
in showing that lung development signaling pathways may be potential targets for prenatal therapy
in CDH.

Both the RA and TGF- signaling pathways have been targets of prenatal therapies in CDH
animal models. RA and vitamin A prenatal therapy reduced the incidence of CDH and severity of
lung hypoplasia in fetuses of nitrofen treated pregnant rats [28]. Interestingly, plasma retinol levels
have been found to be decreased in humans with CDH [3]. Therefore, although nitrofen is not
associated with CDH in humans, the link between the nitrofen-induced CDH rodent model and
human CDH may be the RA signaling pathway itself. Furthermore, prenatal miR-200b therapy in
nitrofen treated pregnant rodents reversed moderate lung hypoplasia and decreased the incidence
of CDH in fetuses [31]. Thus, miR-200b may be a promising new fetal therapy for lung hypoplasia
in CDH.
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In summary, EMT is a critical process during lung development that is regulated by signaling
pathways including RA, TGF-, and Wnt. Previous studies have primarily utilized rodent and
sheep models of CDH. The surgical rabbit model of CDH remains underutilized and is a promising
model for CDH research because rabbit lung development most closely parallels human
physiology.

Purpose:
The purpose of this research is to confirm that our rabbit model of CDH produces pulmonary
hypoplasia which is reversed by TO, and to determine the effects of CDH and TO on lung
development pathways that stimulate EMT, including RA, TGF- and Wnt signaling.

Hypothesis:
We hypothesized that: a) CDH fetuses will have hypoplastic lungs demonstrating low LBWR and
high MTBD; b) CDH fetuses will have decreased expression of lung development genes c) TO
will reverse the effects of CDH pulmonary hypoplasia thereby demonstrating increased LBWR
and decreased MTBD similar to control fetuses; d) CDH+TO fetuses will have similar levels of
lung development markers to control fetuses (Figure 4).
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Figure 4: Proposed Effects of TO on Lung Development. CDH causes lung hypoplasia demonstrated by decreased
LBWR, increased MTBD, and decreased EMT signaling pathway markers. TO reverses the effects of CDH by causing
lung hyperplasia demonstrated by increased LBWR, decreased MTBD, and increased EMT markers, similar to control
lungs.
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CHAPTER 3: MATERIALS AND METHODS
A. Animal Handling and Surgeries
All animal procedures were carried out in strict accordance with the guidelines of the Canadian
Council of Animal Care (CCAC) as approved by the Western University Animal Care Committee
(AUP 2016-041). All efforts were made to minimize suffering as per the approved protocol and
with veterinary oversight. Time dated pregnant New Zealand White rabbits (Charles River,
Sherbrooke) arrived at 13 days gestation. Each month, a group of 5 does arrived at our facility and
were individually housed with free access to water, food, and environmental enrichment (Figure
5) . Each doe underwent two surgeries, a CDH creation at 23 days gestation and a second surgery,
the TO surgery 5 days later at 28 days gestation as previously described [23].

Figure 5: Housing for Pregnant New Zealand White Rabbits. Groups of five time-dated New Zealand White
rabbits were received at 13 days gestation and housed individually with free access to food, water, and environmental
enrichment.
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Pre-operatively, each doe received 0.12 mg/kg Buprenorphine SR SQ (conc. 3 mg/mL, SigmaAldrich Corporation, St. Louis, MO, USA) for analgesia, Penicillin G 300 000 IU IM (Pfizer Inc.,
New York, NY, USA) for the prevention of infection, and Depo-Provera 4.5 mg IM (Pfizer Inc.)
to reduce the risk of spontaneous abortion. Anesthesia was induced with 5 mg/kg IM Ketamine
(conc. 100 mg/mL), 0.15 mg/kg Dexmedetomidine IM (conc. 1 mg/mL, Clearsynth Labs Pvt. Ltd.,
Mumbai, India), 0.01 mg/kg Glycopyrrolate SQ (conc. 0.2 mg/mL, Omega Laboratories Ltd.,
Montréal, QC, Canada), and maintained with 5% Isoflurane (Baxter Healthcare Corporation,
Deerfield, IL, USA) via facemask. Each doe received a 4 cc/kg bolus of 0.9% NaCl SQ, followed
by a maintenance rate of 5 mL/kg/hr. Lacrilube was applied to the eyes and a water circulating pad
was used to maintain normothermia intra-operatively. Soft restraints were used on all 4 limbs to
secure the doe. Vital signs were monitored and maintained within normal limits including heart
rate 180-250, respiratory rate 30-60, and temperature 38-40C.

CDH creation was performed at 23 days of gestation in a total of 75 fetuses. The does were
pre-medicated as described above. The abdominal fur was trimmed, and the abdomen was prepared
with 2% chlorhexidine (Laboratoire Atlas Inc., Montréal, QC, Canada) and draped. A lower
midline laparotomy incision was made and the uterus was exposed. The number of fetuses in each
uterine horn was counted. Two fetuses were chosen from the most ovarian end of each uterine
horn, for a total of 4 fetuses per doe (Figure 6). Fetal position was determined by gentle palpation.
A 1 cm hysterotomy was made on the anti-mesometrial side of the uterus with a #15-blade scalpel
(Aspen Surgical Products Inc., Caledonia, MI, USA) (Figure 7). A purse string suture was placed
using a 6-0 Prolene (Ethicon Inc., Somerville, NJ, USA). The left upper limb of the fetus was
identified, exposed and retracted cephalad. A left-sided thoracotomy was made at the landmark
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between the lateral thoracic vessels using a 25-gauge needle (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) and mosquito forceps (Figure 7). The lung was retracted, exposing the
fetal diaphragm. The diaphragm was grasped with mosquito forceps and a piece was cut with fine
scissors, creating the diaphragmatic defect (Figure 7). The chest wall was sutured with a 6-0
Prolene (Ethicon Inc., Somerville, NJ, USA). The fetus was repositioned into the uterus and the
purse string was tied, thus closing the hysterotomy. The laparotomy incision was closed with a 30 Vicryl (Ethicon Inc., Somerville, NJ, USA) in a running fashion. The skin was closed in a
running subcuticular fashion with a 4-0 Monocryl (Ethicon Inc., Somerville, NJ, USA). Postoperatively, the does were placed under a red warming light and transferred to their housing cage
once mobile. Meloxicam 0.2 mg/kg SQ (conc. 5 mg/mL, Boehringer Ingelheim Vetmedica Inc.,
St. Joseph, MO, USA) was administered every 24 hours for 2 days for post-operative analgesia.

Figure 6: Bicornuate Rabbit Uterus. The pregnant New Zealand rabbit uterus is bicornuate with a right and left
uterine horn containing multiple fetuses. Fetuses located at the ovarian end were used for surgical experimentation.
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Figure 7: CDH Creation in the Rabbit Fetus. A: Hysterotomy with bulging membranes. B: The fetus is minimally
exposed with the left upper limb retracted cephalad and a 25-gauge needle is used to make a skin incision at the
thoracotomy site. C: The diaphragmatic defect is created by grasping a piece of diaphragm and cutting it off with fine
scissors.

TO was performed at 28 days gestation in a total of 17 fetuses. The does were pre-medicated
as described above. Once anesthesia was induced, the abdomen was prepped and draped in a sterile
fashion. The lower laparotomy incision was opened and fetuses were counted. Viability was noted.
Half of the potentially viable CDH fetuses were chosen for TO. A hysterotomy was made and the
fetal head was exposed. The snout was immediately covered with a saline soaked non-woven
sponge to ensure no fetal breathing. A horizontal incision was made at the superior border of the
thyroid gland. A fine snap was used to bluntly dissect down to the trachea. Once isolated, the
trachea was double ligated with a 4-0 Vicryl suture (Ethicon Inc., Somerville, NJ, USA) (Figure
8). Fetal skin was sutured with 6-0 Prolene (Ethicon Inc., Somerville, NJ, USA). The hysterotomy
was closed with 6-0 Prolene (Ethicon Inc., Somerville, NJ, USA) in a running locking fashion.
The doe’s fascia was sutured with 3-0 Vicryl (Ethicon Inc., Somerville, NJ, USA) and the skin
was sutured with 4-0 Monocryl (Ethicon Inc., Somerville, NJ, USA). Post-operative treatment
was as described above.
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Figure 8: Tracheal Occlusion in the Rabbit Fetus. A hysterotomy has been made, the head exposed and neck
extended. A small neck incision was used to isolate the trachea which was double ligated with sutures in order to
perform the TO.

In the last set of 5 does, 10 sham CDH fetuses were generated. Surgical protocol was followed
as previously described. Following CDH creation, two additional fetuses were chosen at the most
ovarian end. A sham CDH was created by performing a left-sided thoracotomy without the creation
of a diaphragmatic defect.

Fetal weights and lung tissue collection was performed at 31 days gestation. Each doe was
euthanized individually in a room away from the remaining does. Each doe was sedated with 1050 mg/kg Ketamine IM (conc. 100 mg/mL) and 2.5-10 mg/kg Xylazine IM (conc. 100 mg/mL,
Bayer Healthcare LLC, Shawnee, KS, USA), and euthanized with 100 mg/kg Pentobarbital
Sodium IV (conc. 50 mg/mL, Oak Pharmaceuticals Inc., Lake Forest, IL, USA) administered
through the ear vein. A midline laparotomy was made and the doe’s heart was palpated to confirm
the absence of cardiac activity. All fetuses were delivered (Figure 9). The snouts were immediately
covered with a saline soaked non-woven sponge and each fetus was decapitated to ensure no fetal
breathing. All fetuses were weighed. A sternotomy and midline laparotomy were performed and
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the diaphragm was assessed for the presence or absence of diaphragmatic defect (Figure 10). The
neck was also incised in CDH+TO fetuses and the trachea was assessed for presence of ligation.
One control unoperated fetus was chosen from each doe containing other surgical specimens and
was selected based on its weight being the average of the litter. Total lung weight and right lung
weight were measured for each fetus and left lung weight was calculated by subtraction (Figure
9). Upper lung lobes were collected and stored in 4% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA, USA) and lower lung lobes were flash frozen in liquid nitrogen and stored
in -80C.

Figure 9: Autopsy Specimens. A: CDH+TO fetus as indicated by the sutures noted in the neck and left chest. The
fetus has been positioned next to small forceps for size comparison. B: Magnified en bloc section of lungs, heart and
trachea. The right and left lungs were further dissected and used in the study whereas the trachea and heart were
discarded.
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Figure 10: Autopsy Confirmation of Diaphragmatic Defect. A: Tip of scissors placed within the diaphragmatic
defect to emphasize presence and size of defect. B and C: Intra-abdominal organs herniating into the chest through
the diaphragmatic defect.

B. Lung Morphology
Right and left upper lobes were immediately stored in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA), for 24 hours and then washed three times in PBS and
stored in 70% Ethanol for 1-3 months. The tissue samples were processed, embedded in paraffin
blocks, and 3-5 m sections were cut. Two slides were made per block of tissue. The slides were
treated with Hematoxylin and Eosin (H&E) staining and stored at room temperature. A compound
light microscope was used and slides were viewed at 100 x magnification. The mean terminal
bronchiole density (MTBD) is inversely proportional to number of alveoli, and is therefore used
as a histologic marker of lung development [22]. The MTBD was calculated by counting the
number of terminal bronchioles in non-overlapping high-power fields per slide [22]. Slides were
de-identified and numbered so that the study group was not known at the time of MTBD
calculation. An Aperio ScanScope slide scanner was used to take representative pictures of control,
sham CDH, CDH, and CDH+TO lung slides (Figure 11).
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Figure 11: H&E Stained Fetal Rabbit Lung Sections. H&E stained lung sections showed more dense tissue with
increased number of mean terminal bronchioles in hypoplastic CDH lungs compared to control and sham CDH. The
histologic appearance of CDH+TO sections was less dense with fewer mean terminal bronchioles. A representative
picture is shown from each group: A. Control; B. Sham CDH; C. CDH; D. CDH+TO. The yellow arrows point to
terminal bronchioles.

C. RT-qPCR Studies
i.

mRNA

Right and left lower lobes were flash frozen in liquid nitrogen and stored at -80C. The left
lower lobe lung tissue was ground with a mortar and pestle in liquid nitrogen. Total cellular RNA
was extracted using TRIzolTM Reagent (Thermo Fisher Scientific, Waltham, MA, USA) according
to the manufacturer’s protocol. RNA concentration and purity were determined using the
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). RNA integrity
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was evaluated with 1.5% agarose gel-electrophoresis and Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). RNA samples with an RNA integrity number (RIN) greater than 8 were
included in the study. RNA was converted to single strand complementary DNA (cDNA) with a
High-Capacity RNA-to-cDNATM Kit (Thermo Fisher Scientific, Waltham, MA, USA) as per
manufacturer’s protocol using a BioRad C1000 thermal cycler (BioRad, Hercules, CA, USA).
cDNA was diluted 1:40 with RNase-free water and stored at -20C. Primer optimization was
performed for reference genes (SDHA, ATCB, TOP1) and genes of interest (Wnt2, BMP4, Lgl1,
PDE5A, MKI67, WIF1). Primers were tested by performing a temperature gradient protocol and
calculating primer efficiencies using a 4-fold dilution series. Primers with efficiencies ranging
between 90-110% were considered acceptable and used in the study (Table 1). Real time
quantitative polymerase chain reaction (RT-qPCR) was performed in triplicate on a BioRad
CFX384 (BioRad, Hercules, CA, USA), with the following cycling conditions: 95C for 10
minutes, followed by 43 cycles of 95C for 10 seconds, 60C for 10 seconds and 72C for 15
seconds. RT-qPCR reactions consisted of 1x final concentration of SensiFast SYBR No-ROX mix
(FroggaBio, Toronto, Canada) primer at 200 nM final concentration, and 3 L 1:40 cDNA
template, in a total 8 L reaction volume. RT-qPCR results were analyzed using the BioRad
CFX384 software (2-Ct method).

ii.

MicroRNA

RNA was converted to cDNA using the miScript II RT Kit (Qiagen, Hilden, Germany) and
cDNA was diluted with 200 L RNase-free water according to the manufacturer’s protocol.
miRNA assays were reconstituted in 550 L TE Buffer (pH 8.0). Endogenous control (U6, miR103, miR-191) and target (miR-33, miR-200b, miR-375) assay (Qiagen, Hilden, Germany)
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efficiencies were determined using a 2-fold dilution series. miRNA assays with efficiencies
ranging between 90-110% were considered acceptable and used in the study (Table 2). RT-qPCR
reactions were conducted using the miScript SYBR Green PCR Kit (Qiagen, Hilden, Germany).
The 10 L volume reactions consisted of 5 L 2x QuantiTect SYBR Green PCR Master Mix, 1
L 10x miScript Primer Assay, 1 L 10 x miScript Universal Primer (Qiagen, Hilden Germany),
2 L RNase-free water, and 1 L Template cDNA. RT-qPCR was performed in triplicate on a
BioRad CFX384 with the following cycling conditions: 95C for 15 minutes, followed by 40
cycles of 94C for 15 seconds, 55C for 30 seconds, and 70C for 30 seconds. RT-qPCR results
were analyzed using the BioRad CFX384 software (2-Ct method).

D. Statistical Analysis
The Shapiro-Wilk test of normality was performed for all data sets. Non-parametric data was
analyzed with the Kruskal-Wallis test. Parametric data was analyzed using the one-way ANOVA
with Tukey’s post hoc analysis. Statistical significance was considered to be p < 0.05. Body
weight, lung weight, and surgical times were presented as mean + SEM. Lung body weight ratio
(LBWR) and mean terminal bronchiole density (MTBD) were presented as box and whisker plots
with the box showing the range of values from the 25th to 75th percentile, the line within the box
representing the mean, and the whiskers showing the maximum and minimum values. RT-qPCR
data was presented as relative quantification (RQ) and error bars (RQ max, RQ min) were derived
from the standard deviation (SD) using BioRad CFX384 software (2-Ct method). Correlation
graphs were created to explore the relationship between mRNA/miRNA targets and degree of lung
hypoplasia (LBWR and MTBD). Linear regression analysis was performed for the correlation
graphs and the squared Pearson correlation coefficient (R2) and p-values were reported.
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Table 1: Reference and GOI Primer Sequences, Efficiencies, R2, and Literature Resources Used for RTqPCR
Reference
Gene
ATCB
SDHA
TOP1
Gene of
Interest
Wnt2
BMP4
Lgl1
PDE5A
MKI67
WIF1

Target Sequence (5’-3’)

E (%)

R2

Reference Paper

F: GATCTGGCACCACACCTTCT
R: TGATCTGGGTCATCTTCTCG
F: ATCTATCAGCGTGCGTTCG
R: ATCAGCCACACAGCAGCAT
F: GCAGGCAATGAGAAGGAAGA
R: CACGTACTCCTGACCATCCA
Target Sequence (5’-3’)

107.0

0.95

Vuckovic et al 2013 [23]

96.6

0.99

Vuckovic et al 2013 [23]

99.0

0.99

Vuckovic et al 2013 [23]

E (%)

R2

Reference Paper

F: GGATGACCAAGTGCGAGTGT
R: GTCCAGTCAGCACTCTTGGG
F: ACAATGTGACACGGTGGGAA
R: CCTGATGGGTCCGTGTATGG
F: GCCAAGATCCTCATCGGCTA
R: AGGAAGAGGTGGTCCACACA
F: CTTGGGCTACACCAACAACC
R: CCTCGGTTCAATGCAGAAGT
F: AGGCAGGTGAACAAAAGACC
R: ATGAGCCCTCCCTATGACAA
F: GTATGAACGGCGGACTTTGT
R: GTCCTGGTGGGCAAATACAT

100.0

0.97

97.0

0.98

102.0

0.97

105.5

0.99

Emmerton-Coughlin et al 2014
[42]
Emmerton-Coughlin et al 2014
[42]
Emmerton-Coughlin et al 2014
[42]
Engels et al 2016 [43]

96.6

0.98

Engels et al 2016 [43]

100.7

0.99

Engels et al 2016 [43]

Table 2: Endogenous Control and micro-RNA miScript Primer Assays, Efficiencies, R2, and Literature
Resources Used for RT-qPCR
Target Sequence (5’-3’)

E (%)

R2

Reference Paper

98.4

0.95

Pereira-Terra et al
2015 [19]

Rn-miR-103
Mm-miR-191
Micro-RNA
Rn-miR-33

GTGCTCGCTTCGGCAGCACATATACTAAA
ATTGGAACGATACAGAGAAGATTAGCATG
GCCCCTGCGCAAGGATGACACGCAAATTC
GTGAAGCGTTCCATATTTTT
AGCAGCAUUGUACAGGGCUAUGA
GCUGCACUUGGAUUUCGUUCCC
Target Sequence (5’-3’)
GUGCAUUGUAGUUGCAUUGCA

95.4
99.8
E (%)
101.3

0.98
0.85
R2
0.89

Rn-miR-200b

UAAUACUGCCUGGUAAUGAUGAC

95.6

0.88

Rn-miR-375

UUUGUUCGUUCGGCUCGCGUGA

98.0

0.94

Peltier et al 2008 [61]
Peltier et al 2008 [61]
Reference Paper
Zhu et al 2016
[50]
Pereira-Terra et al
2015 [19]
Song et al 2015 [62]

Endogenous
Control
RNU6-2
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CHAPTER 4: RESULTS
A. Fetal Surgery
Fetal surgeries were performed from the period of September to December 2017 and are
summarised in Figure 12. Briefly, four groups of five pregnant does per group were operated on
in total. There was a total of nineteen pregnant does as one doe was not pregnant at the time of
operation and was immediately euthanized. Collectively the does produced a total of 222 fetuses.
Overall, 137 of the 222 fetuses survived from the time of first surgery to the time of euthanasia,
while 85 were dead at the time of organ retrieval. Fifty-eight diaphragmatic defects were created
for the CDH group. Sixteen of the CDH fetuses survived. One CDH fetus was excluded on autopsy
due to the absence of a diaphragmatic defect. As a result, a total of 15 CDH fetuses were included
in the study. A total of 17 CDH+TO operations were performed, of which 16 survived. One
CDH+TO fetus was excluded on autopsy due to the absence of diaphragmatic defect, which
resulted in a total of 15 CDH+TO specimens in the study. Ten left thoracotomies were performed
to create a sham CDH group. Six of these sham CDH fetuses survived and were included in the
study. In addition to our surgical specimens, one average sized unoperated fetus was chosen from
every doe that also contained other surgical specimens, resulting in a total of 15 control fetuses.
Therefore, 51 total fetuses were included in the study – 15 control, 15 CDH, 15 CDH+TO, and 6
sham CDH. The mean total operative time for CDH creation was 1 hour and 8 minutes + 2 minutes
per doe while the mean cut time, which excluded anesthesia time, was 46 + 2 minutes. TO mean
total operative time was 43 + 2 minutes per doe and mean cut time was 18 + 2 minutes (Table 3).
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Figure 12: Fetal Rabbit Surgery Flowchart. Four biological groups were created – control, sham CDH, CDH, and
CDH+TO. 58 CDH fetuses were created, 16 survived, and 1 was excluded on autopsy due to absence of diaphragmatic
defect (DD). 17 CDH+TO were created, 16 survived, and 1 was excluded on autopsy due to absence of DD. 10 sham
CDH were created and 6 survived. 15 average sized fetuses were chosen from 98 viable unoperated control specimens.
There were 51 total specimens included in the study – 15 control, 6 sham CDH, 15 CDH, and 15 CDH+TO.

Table 3: Pregnant Rabbit Doe Weights and Surgical Times. Weight of pregnant does at each surgery timepoint
and surgical times presented as mean + SEM. The mean total OR time includes the anesthesia and operative time.
Mean cut time refers to the time during which surgery was performed, from initial incision to final skin closure.

Mean Doe Weight

Mean Total OR Time

Mean Cut Time

(kg)

(hr:min)

(hr:min)

CDH Creation

4.01+ 0.6

1:08 + 0.02

0:46 + 0.02

TO Creation

3.89 + 0.6

0:43 + 0.02

0:18 + 0.02

Delivery

3.92 + 0.15

⎯

⎯

35
B. Anatomic Features
The size of diaphragmatic defect was noted on autopsy and subjectively measured as small
(+), moderate (++) or large (+++) (Table 4). Each sham CDH fetus had a left-sided thoracotomy
and was confirmed to have an intact diaphragm with no defect. Within the CDH group, 8 fetuses
had a large CDH with liver herniating into the left chest, and occasionally the spleen and stomach.
The CDH group also contained 6 moderate diaphragmatic defects which were large but did not
have intra-abdominal contents herniating into the chest at the time of autopsy. One fetus had a
small diaphragmatic defect. The CDH+TO group had 10 large and 5 moderate diaphragmatic
hernias. The initial mean doe weight at time of CDH creation was 4.01 + 0.06 kg, 3.88 + 0.06 kg
at TO, and 3.92 + 0.15 kg at time of euthanasia and organ retrieval (Table 3).

The mean fetal body weight was similar in control, sham CDH, CDH, and CDH+TO
fetuses (Table 5). Total lung weight was significantly decreased in CDH fetuses compared to
control fetuses and significantly increased in CDH+TO fetuses compared to CDH fetuses (Table
5). Similarly, right and left lung weights were lower in CDH compared to control and higher in
CDH+TO compared to CDH fetuses (Table 5). Right and left lung weights were similar within
each group except in the CDH+TO fetuses, where right lungs were larger than left (p=0.04). The
LBWR was significantly lower in the CDH group compared to control fetuses (p=0.01, Figure 13).
The LBWR significantly increased in CDH fetuses following TO (p=0.005, Figure 13).
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Table 4: Size of Diaphragmatic Defects on Fetal Rabbit Autopsy. The size of diaphragmatic defect was
subjectively measured. Large defects involved solid organs such as the liver herniating into the chest cavity. The
number of fetuses are categorized by the size of diaphragmatic defect.

Control

Small

Moderate

Large

(+)

(++)

(+++)

⎯

⎯

⎯

0

0

0

1

6

8

0

5

10

(n=15)
Sham CDH
(n=6)
CDH
(n=15)
CDH+TO
(n=15)
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Table 5: Rabbit Fetal Body and Lung Weight Measurements. CDH fetuses had smaller total lung weight, right
lung weight, left lung weight, and LBWR compared to control (p=0.008, p=0.03, p=0.002 respectively). CDH+TO
total lung weight, right lung weight, left lung weight, and LBWR were increased compared to CDH fetuses (p=0.001,
p=0.0009, p=0.02 respectively). Fetal body weights were similar in all groups. Weights and LBWR presented as mean
+ SEM. Statistics calculated with one-way ANOVA and Tukey’s post-hoc analysis.
Fetal

Body

Weight (g)

Total

Lung

Weight (g)

Right Lung

Left Lung Weight (g)

Weight (g)

Lung Body Weight Ratio (LBWR)
(Lung weight /body weight (g))

Control
37.49 + 2.16

0.92 + 0.05

0.48 + 0.03

0.43 + 0.03

0.025 + 0.0015

41.88 + 5.38

0.81 + 0.14

0.47 + 0.08

0.32 + 0.07

0.020 + 0.0024

34.19 + 2.17

0.52 + 0.06*

0.30 + 0.03*

0.22 + 0.03*

0.016 + 0.0016*

36.47 + 1.87

0.94 + 0.10*

0.56 + 0.06*

0.39 + 0.07*

0.026 + 0.0030*

(n=15)
Sham CDH
(n=6)
CDH
(n=15)
CDH+TO
(n=15)
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Lung Body Weight Ratio (LBWR)
0.06

Lung weight/Body weight (g)

p=0.01

p=0.005

0.04

0.02

0.00

Control
(n=15)

Sham CDH
(n=6)

CDH
(n=15)

CDH+TO
(n=15)

Figure 13: Lung Body Weight Ratio (LBWR) in Fetal Rabbits. LBWR was significantly decreased in CDH fetuses
compared to control (p=0.01) and CDH+TO (p=0.005) fetuses. LBWR was similar in CDH+TO and control fetuses.
Control n=15, Sham CDH n=6, CDH n=15, and CDH+TO n=15. Box and whisker plot shows the range of values
from the 25th to 75th percentile, the line within the box depicts the mean, and the whiskers show the maximum and
minimum values. Statistical analysis performed using one-way ANOVA and Tukey’s post hoc analysis.

C. Lung Morphology
The right upper lobe (RUL) and left upper lobe (LUL) was processed from each biological
specimen: control n=15, sham CDH n=6, CDH n=15, CDH+TO n=15 (Figure 14). Each lung lobe
was processed, and two representative slides were made per block of tissue: control – RUL n= 30,
LUL n = 30; sham CDH – RUL n = 12, LUL n=12; CDH – RUL n=30, LUL n=30; CDH+TO –
RUL n =30, LUL n=30 (Figure 14). Therefore, 204 fetal rabbit lung slides were analyzed in total.
There was no difference in MTBD between right and left upper lobes within each group – control
6.05 vs 6.03 (p=0.43), sham CDH 5.42 vs 4.96 (p=0.47), CDH 10.34 vs. 9.79 (p=0.49), and
CDH+TO 5.33 vs. 6.98 (p=0.09) (Figure 14). The MTBD was significantly higher in CDH fetuses
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compared to control and sham CDH fetuses (p<0.0001 and p=0.0001 respectively, Figure 14).
MTBD was significantly decreased in CDH fetuses following TO (p<0.0001, Figure 14). MTBD
in CDH+TO fetuses was similar to control and sham CDH fetuses. The histologic appearance of
lung specimens showed more dense-appearing tissue with increased number of terminal
bronchioles in CDH compared to control and sham CDH, and less dense tissue with fewer mean
terminal bronchioles in CDH+TO specimens (Figure 11).

Mean Terminal Bronchiole Density (MTBD)
p < 0.0001

Number of terminal bronchioles
per high powered field (100x Mag)

25

p < 0.0001

p = 0.0001
20

15

10

5

0
RUL

LUL

Control
(n=15)

RUL

LUL

Sham CDH
(n=6)

RUL

LUL

CDH
(n=15)

RUL

LUL

CDH+TO
(n=15)

Figure 14: Mean Terminal Bronchiole Density (MTBD) in Fetal Rabbit Lungs. MTBD was significantly
increased in CDH fetuses compared to control, sham CDH, and CDH+TO fetuses (p<0.0001, p=0.0001, and p<0.0001,
respectively). CDH+TO had decreased MTBD that was similar to control and sham CDH. MTBD was similar in RUL
and LUL within each group. Biological groups: control n=15, sham CDH n=6, CDH n=15, and CDH+TO n=15.
Slides: control – RUL n= 30, LUL n = 30; sham CDH – RUL n = 12, LUL n=12; CDH – RUL n=30, LUL n=30;
CDH+TO – RUL n =30, LUL n=30. Box and whisker plot shows the range of values from the 25 th to 75th percentile,
the line within the box depicts the mean, and the whiskers show the maximum and minimum values. Statistical analysis
performed using one-way ANOVA and Tukey’s post hoc analysis.
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D. RNA Results
RNA was extracted from 51 left lower lobe (LLL) lung tissue samples (Figure 15). Following
RNA integrity testing, 6 samples were excluded due to poor quality RNA containing an RNA
integrity number (RIN) < 8 (Figure 15). These samples were ultimately excluded because there
was no remaining lung tissue left for these samples and further RNA extraction could not be
performed. Therefore, a total of 46 RNA samples were included in the study – 14 control, 6 sham
CDH, 12 CDH, and 14 CDH+TO RNA samples (Figure 15).

Figure 15: Fetal Rabbit RNA Sample Flowchart. RNA was extracted from 51 left lower lobe (LLL) lung tissue
samples. The samples were tested for RNA integrity and 5 were excluded due to poor quality RNA and inadequate
tissue. There were 46 total RNA samples included in the study: 14 control, 6 sham CDH, 12 CDH, and 14
CDH+TO.
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E. RT-qPCR Results
The relative expression of Wnt2 was similar in all groups: control=1.00 (1.29, 0.78), sham
CDH=1.24 (1.61, 0.96), CDH=1.31 (1.73, 1.00), CDH+TO=1.14 (1.65, 0.79) (p=0.1, Figure 16).
BMP4 expression was also unchanged: control=1.00 (1.29, 0.77), sham CDH=1.11 (1.29, 0.96),
CDH=1.05 (1.3, 0.85), CDH+TO=1.05 (1.37, 0.8) (p=0.8, Figure 16). Lgl1 was significantly lower
in CDH+TO fetuses compared to CDH and sham CDH fetuses (p=0.03 and p=0.006, respectively):
control=1.00 (1.31, 0.76), sham CDH=1.17 (1.65, 0.83), CDH=1.16 (1.55, 0.87), CDH+TO=0.82
(1.02, 0.65) (Figure 16).

PDE5A expression was similar in all groups: control=1.00 (1.42, 0.70), sham CDH=1.15 (1.48,
0.90), CDH=1.12 (1.41, 0.89), CDH+TO=0.89 (1.20, 0.66) (p=0.09, Figure 17). WIF1 expression
was also unchanged: control=1.00 (1.58, 0.63), sham CDH=0.61 (1.38, 0.27), CDH=0.8 (1.39,
0.46), CDH+TO=1.02 (1.98, 0.52) (p=0.3, Figure 17). MKI67 expression was significantly
increased in CDH+TO compared to control fetuses: control=1.00 (1.68, 0.60), sham CDH=1.02
(1.83, 0.57), CDH=1.14 (1.67, 0.78), CDH+TO=1.9 (3.46, 1.04) (p=0.01, Figure 17).

miR-33 expression was significantly higher in CDH+TO fetuses compared to sham CDH
fetuses: control=1.00 (2.29, 0.44); sham CDH=0.46 (1.21, 0.17); CDH=0.66 (1.19, 0.37);
CDH+TO=1.24 (2.19, 0.71) (p=0.03, Figure 18). The relative expression of miR-200b was similar
in all groups: control=1.00 (1.24, 0.80); sham CDH=0.88 (1.01, 0.76); CDH=1.07 (1.35, 0.84);
CDH+TO=1.02 (1.30, 0.80) (p=0.39, Figure 18). There were also no changes in the expression of
miR-375: control=1.00 (1.36, 0.74); sham CDH=0.99 (1.41, 0.70); CDH=1.25 (1.90, 0.83);
CDH+TO=1.16 (1.59, 0.84) (p=0.32, Figure 18).

42
Figure 16: Relative Expression of Wnt2,
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Relative Quantification (2-(ΔΔCt))

Figure 17: Relative Expression of PDE5A,
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Figure 18: Relative Expression of miR-33,

miR-33
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Correlation graphs showed that there were weak correlations with no significant relationship
between most target mRNAs and miRNAs versus LBWR and MTBD (Supplementary Material).
Interestingly, there was a pattern observed in the CDH+TO group that showed a positive
relationship between Wnt2 vs MTBD (R2=0.13, p=0.20), BMP4 vs MTBD (R2=0.25, p=0.07),
Lgl1 vs MTBD (R2=0.22, p=0.09), and a significant positive relationship between PDE5A vs
MTBD (R2=0.31, p=0.04) (Figure 19).
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Figure 19: The Relationship of Wnt2, BMP4, Lgl1, and PDE5A Expression vs MTBD in CDH+TO Fetal Rabbit
Lungs. There is a positive relationship between Wnt2 vs MTBD (R2=0.13, p=0.20), BMP4 vs MTBD (R2=0.25,
p=0.07), Lgl1 vs MTBD (R2=0.22, p=0.09), and PDE5A vs MTBD (R2=0.31, p=0.04). Control n=14, Sham CDH
n=6, CDH n=12, and CDH+TO n=14.
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CHAPTER 5: DISCUSSION & CONCLUSION
Fetal lung development is controlled by several intricate cellular pathways including RA, TGF , and Wnt signaling. These pathways all contribute to epithelial-mesenchymal transition (EMT),
a critical component of early lung development. Wnt signaling is highlighted in the current study
because this essential signaling pathway has not been thoroughly explored in the context of lung
development in CDH. However, in addition to Wnt signaling, components of other critical EMT
pathways were also explored. The Wnt signaling pathway involves miR-33, miR-375, Wnt2,
BMP4, and WIF1. miR-200b targets TGF- signaling, which may be linked to PDE5 expression.
Lgl1 is a downstream member of the RA pathway and stimulates alveolarization. MKI67 is a
marker of cell growth and can be used as an indicator of lung development. The purpose of this
study was to establish a rabbit model of CDH and determine the effects of TO on EMT pathways
of lung development. In the current study, TO increased miR-33 and MKI67 expression, while
Lgl1 mRNA expression was decreased in CDH+TO fetuses. miR-200b, miR-375, Wnt2, BMP4,
PDE5A, and WIF1 levels were unchanged (Figure 20).
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Figure 20: Proposed EMT Pathways of Fetal Lung Development. This pathway includes Wnt, TGF-, and RA
signaling. miRNAs and mRNAs investigated in the current study are bolded: Wnt signaling pathway – miR-33, miR375, Wnt2, BMP4, WIF1; RA signaling pathway – Lgl1; TGF- signaling pathway – miR-200b, PDE5A; and cell
proliferation marker, MKI67.

The surgical rabbit model is useful for CDH research because the diaphragmatic defect is
created during the pseudoglandular stage, similarly to humans, and thus most closely reflects the
effects of CDH in human lung development [24]. In addition, the rabbit has a short gestation and
produces large litters. Unlike nitrofen induced CDH rodent models, surgical models are ideal in
the study of TO and other interventions for CDH since there is no concern about the effect of
nitrofen on the developing lung or other organs [6]. The surgical sheep model has also been used
in CDH research, however, CDH is created later in gestation during the canalicular stage which
does not reflect the human condition [42,63]. Sheep also have a much longer gestational period of
145-149 days, produce fewer fetuses and is a much more costly model [6]. Despite the benefits of
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the rabbit model of CDH, it has been under-utilized and remains outnumbered by nitrofen-induced
rodent models of CDH due to increased cost and technical difficulty. Of the published rabbit CDH
papers, only a few have studied the effects of TO, and to the best of our knowledge, none have
studied the impact of CDH and potential rescue effects of TO on the Wnt signaling pathway
[43,64,65] (Figure 20).

This rabbit model of CDH and TO was successfully replicated and physiologically consistent
with previously published data. The learning curve and difficulty of performing fetal rabbit surgery
accounted for non-survivors in this study. The survival rate of CDH fetuses was 27% in this study
compared to 41% in previously reported data [66]. It is important to note that in previous studies
fetuses were exposed to only one surgery, CDH creation, whereas in this study all fetuses also
underwent a second operation. Therefore, the 10% increase in mortality in this study is likely due
to increased stress to fetuses due to a second operation. In addition, sham CDH fetuses likely died
due to operative stress and prolonged operative time because this surgery was added to each doe
that was also already undergoing CDH creation and TO.

Furthermore, the size of diaphragmatic defects on autopsy were subjectively measured with
only one defect noted to be small with no intra-abdominal contents herniating into the thoracic
cavity, whereas the remaining defects were either moderate or large with the liver and other intraabdominal organs herniating into the chest. These defects are analogous to the more severe cases
of CDH in humans that would quality for FETO. Interestingly, the size of diaphragmatic defect
has not been reported in other CDH animal studies.
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In this study, CDH induced lung hypoplasia was confirmed with quantification of LBWR and
MTBD (Figure 13 and 14). Decreased LBWR and increased MTBD are markers of lung
hypoplasia and are commonly used to define lung hypoplasia in CDH literature [22–24,66]. Lung
hypoplasia that was induced through CDH was subsequently reversed by TO as postulated [23,43].
Interestingly in this study, both right and left lungs were hypoplastic in CDH and hyperplastic
following TO according to both weight and MTBD. On a mechanical level, TO is thought to work
by fluid building up in the lung, thus causing stretch-induced lung growth and maturation
[23,67,68]. Although it is well established that TO reverses pulmonary hypoplasia in human CDH
babies and animal CDH models, the molecular mechanism and effect on lung development
signaling pathways is not fully understood [1]. This continues to be an area requiring further
exploration with the potential for determining molecular prenatal therapies for CDH associated
lung hypoplasia that stimulate lung development. miR-200b and RA have recently been explored
as prenatal therapies in CDH animal models, which poses an exciting area for future translational
research [31,45].

Wnt signaling is critical in lung development and plays an important role in EMT during early
stages, which ultimately regulates proximal-distal patterning, including branching morphogenesis,
during later stages of lung development [37,69–71]. MKI67 is a cell proliferation marker that has
been studied in the context of the canonical Wnt/-catenin signaling pathway in embryonic lung
growth [72]. Similar to other reports, in the current rabbit CDH study, MKI67 was significantly
upregulated by TO compared to control fetuses (Figure 17) [43].
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Wnt2 is part of the canonical Wnt/ catenin signaling pathway and BMP4 is a downstream
target of this pathway [69,73]. In a previously reported study of Wnt2 and BMP4 in the nitrofeninduced CDH rodent model, fetuses were sacrificed at multiple time points during the gestational
period, and gene expression was therefore analyzed during different stages of lung development
[37]. The overall trend of Wnt expression was that Wnt2 was highly expressed during early lung
development in normal control fetuses, decreased over time, and was low at term on E21 [37].
Wnt2 and BMP4 expression was decreased in CDH lungs compared to control on E15 during early
stages of lung development [37]. In CDH fetuses, Wnt2 and BMP4 expression increased over the
gestational period and was similar to control fetuses at term on E21 [37]. In the ovine surgical
model of CDH, there was no significant difference in Wnt2 expression in CDH fetal sheep
compared to control sheep at term gestation [42]. In the current study, Wnt2 and BMP4 expression
was similar in control, sham CDH, CDH, and CDH+TO fetal rabbit lungs (Figure 16). All of these
lung specimens were taken at term and gene expression was analyzed during late stages of lung
development. These results may be explained by the dynamic expression of Wnt signaling pathway
genes during different stages of lung development, and are consistent with the current literature.
In future studies, to further confirm Wnt expression, gene analysis should be performed during
each stage of lung development in order to capture the changes in expression that occur during
fetal lung development.

WIF1 is a Wnt inhibitor factor that inhibits Wnt proteins by targeting SMAD1 in epithelial
cells during lung development [43,74]. WIF1 expression was similar in control, sham CDH, CDH,
and CDH+TO fetuses (Figure 17). Although these WIF1 expression results are not consistent with
the literature, previously reported WIF1 data in rabbit and rodent CDH models also presents
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conflicting results [43,75]. WIF1 was upregulated in CDH fetal rabbits and downregulated
following TO [43]. However, SMAD1 and WIF1 were downregulated in the nitrofen-induced
rodent model of CDH during the saccular stage of lung development on E18 and E21 [43,75]. The
variation in these findings could be due to differences in species-specific gene expression, the
mode and timing of CDH induction, and the stage of lung development at which time the lung
tissue was analyzed. For example, WIF1 expression in a sample of lung tissue collected during
early lung development stages may be different than a sample collected at term during late stages
of lung development. It is also important to note that earlier reports of gene expression in the rabbit
model of CDH have been conducted with small animal numbers of 3-4 per group and in the current
report animal groups consisted of 12-14 fetuses per group. These larger numbers were based on
power calculations using pilot study data that compared MTBD results between CDH and control
fetuses (Supplementary Material).

EMT is regulated by the Wnt signaling pathway and this process is also complemented by the
RA signaling pathway of lung development. Lgl1 is a downstream target of the RA signaling
pathway and plays an important role during late stages of lung development as a regulator of
branching morphogenesis and alveolarization [42,44,45,76–78]. Discrepancies in Lgl1 expression
between the rabbit and other models were also identified. In the current study, Lgl1 expression in
CDH rabbit fetuses was similar to control fetuses, but downregulated in CDH+TO fetuses
compared to sham CDH fetuses (Figure 16). Lgl1 in the rat and sheep CDH models has been
previously observed to be downregulated [42][45]. Possible explanations for these discordant
findings are that different models (i.e. chemical vs surgical) involve different pathways or
mechanisms, so prenatal interventions such as TO will have different effects [43]. Different species
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have variable lengths of gestation and therefore different time frames for the stages of lung
development [43]. At term gestation, fetal rabbits are in the process of alveolarization which begins
in the prenatal period and continues in the post-natal period, similar to humans. In comparison,
alveolarization is complete in fetal sheep at term gestation, and does not begin until the post-natal
period in rodents [24]. Since Lgl1 is primarily involved in alveolarization, downregulation of Lgl1
following TO could be due to negative feedback from the completion of alveolarization as a result
of the compensatory effects of TO.

In the current study, PDE5A expression was observed to be consistent across the animal groups
(Figure 17). However, there was a significant positive correlation between PDE5A expression and
degree of lung hypoplasia (Figure 19). This suggests that PDE5A expression is decreased in less
hypoplastic lungs with decreasing MTBD in CDH+TO fetal rabbits. This is consistent with
previous reports of increased PDE5A expression in CDH fetal rabbits and decreased expression in
CDH+TO fetuses [43]. PDE5A is a member of the phosphodiesterase (PDE) family and functions
as an enzyme that metabolizes cGMP in the lung [79]. Interestingly, some PDEs are altered in
TGF- induced EMT, although this has mostly been shown in PDE4 [46]. Fetal pulmonary
hypertension is mediated by PDEs, such as PDE5, which counteract cAMP and cGMP vasodilatory
pathways in the lung [47]. PDE5 is prevalent in the lung and in normal lungs its expression
increases to the end of gestation and then rapidly decreases after birth [47]. During normal fetal
lung development, the formation of pulmonary vasculature parallels the development of the
bronchial tree [47]. In utero, pulmonary hypertension is normal for fetuses [47]. Pulmonary
pressures are equivalent to systemic pressures as the placenta, and not the lung, performs the
majority of gas exchange for the fetus [47]. During the gestational period, rapid vascular growth
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occurs in preparation for the shift to lung gas exchange after birth [47]. In CDH, abnormal vascular
development results in pulmonary vascular hypoplasia, decreased pulmonary blood flow, and
abnormal pulmonary vasoconstriction which exacerbates pulmonary hypertension and causes it to
persist after birth [47]. Clinically, PDE5 inhibitors such as Sildenafil are used to treat pulmonary
hypertension due to their smooth muscle relaxation properties [80]. The treatment of rats with
Sildenafil induced alveolar and vascular growth, suggesting that PDE5 may play a role in both
alveologenesis and angiogenesis [81].

Recently it has become apparent that a complex interplay occurs between miRNAs and
mRNAs. miRNAs are non-coding RNAs that function as post-transcriptional regulators of gene
expression [56]. miR-33 is an upstream regulator of the Wnt signaling pathway and was found to
be downregulated in CDH rat fetuses [50]. In the current study, miR-33 was upregulated in our
CDH+TO fetuses compared to sham CDH fetal rabbit lungs (Figure 18). There was a decrease in
miR-33 expression in CDH fetuses, however, this was not statistically significant (Figure 18).
miR-33 targets high mobility group AT-hook 2 (HMGA2) in the canonical Wnt/-catenin
signaling pathway [50,82]. HMGA2 is essential in cell proliferation and epithelial differentiation
during embryogenesis [72]. HMGA2 knockout enhances Wnt signaling by decreasing Wnt
antagonizing proteins, GATA binding protein 6 (GATA6) and FZD2 [72]. During early stages of
lung development in the nitrofen-induced CDH rodent model, GATA6 was downregulated along
with Wnt2 and its downstream target BMP4 [37]. The role of miR-33 in fetal lung development
has not been thoroughly investigated. Interestingly, miR-33 appears to stimulate fetal lung
development, rather than inhibit cell growth as previously reported for lung cancer cells. miR-33
expression plays a inhibitory role in cellular development of lung cancers, and decreases lung
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carcinogenesis and metastasis [83]. miR-33a upregulation inhibits EMT, growth, and metastasis
of non-small cell lung cancer cells [84,85]. miR-33b suppresses tumor cell growth and EMT by
inhibiting Wnt/-catenin signaling in lung adenocarcinoma cells [83]. miR-33b was also found to
inhibit proliferation of lung squamous cell carcinoma [86]. miR-33 could be used as a potential
therapeutic target in lung adenocarcinoma, and due to its tumor-suppressive properties, it has been
proposed that miR-33 be used as a prognostic marker or a therapeutic target for lung cancers [83–
86]. In general, previous research has been heavily focused on miR-33 in the context of lung
cancer, so the role of miR-33 in fetal lung development is a potentially exciting area for further
study.

In the current study, miR-375 expression was similar in all animal groups and was unaltered
by CDH and TO (Figure 18). miR-375 has not yet been studied in the context of CDH. During
lung development, miR-375 inhibits the Wnt/-catenin signaling pathway by targeting FZD8
[57,58]. Overexpression of miR-375 inhibited alveolar epithelial trans-differentiation in fetal rat
lungs at term gestation [58]. miR-375 expression increased throughout development as was
significantly elevated at term during the saccular stage compared to the earlier canalicular stage
[58]. This is consistent with previously reported data that shows a decreasing trend in Wnt2
expression throughout lung development stages in fetal rats [37]. Although miR-375 appeared to
be elevated in CDH rabbit fetuses in the current study, this was not significantly different compared
to the other animal groups (Figure 18). The literature suggests that miR-375 expression varies with
developmental stage. Therefore, differences in the current study’s results and previously reported
data may be due to the inability to capture changes in gene expression during the different stages
of lung development in the current study since all specimens were collected at term gestation. This
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multi-stage tissue collection approach is important in determining the role of miR-375 and crucial
in order to adequately compare expression to previously reported data in other animal models.

EMT in fetal lung development is also regulated by the TGF- signaling pathway [31,87].
miR-200b regulates TGF- signaling in a negative feedback loop by targeting transcription factors
zinc finger e-box binding homeobox 1 (ZEB1) and ZEB2 [19,31]. miR-200b has been specifically
identified in the peripheral lung of mice, where it regulates epithelial and fibroblast cell
differentiation in distal lung airway development [48]. miR-200b was upregulated in human
fetuses with CDH, and even further upregulated in the tracheal fluid of FETO responders [19].
miR-200b was also upregulated in the rabbit model of CDH, however, variable changes in miR200b expression were identified following TO [64]. In the rodent model of CDH, miR-200b
expression was dependent on both the region of lung tissue and stage of lung development. miR200b expression was decreased in the mesenchyme and epithelium of rat CDH lungs in early lung
development, during pseudoglandular and canalicular stages, compared to control lungs [31].
However, miR-200b expression was similar to control fetuses at term during the saccular stage of
lung development [31]. In addition, miR-200b became localized in the proximal epithelium of
large airways compared to distal terminal saccules [31]. Furthermore, miR-200b prenatal therapy
in nitrofen rats reduced the incidence of CDH fetuses [31]. In our current study, there was no
difference in miR-200b expression in control, sham CDH, CDH, and CDH+TO fetal rabbit lungs
(Figure 18). These findings were similar to the previously reported rodent data that showed similar
levels of miR-200b at term gestation. The disadvantage of our rabbit study was that we were not
able to capture the distribution pattern of miR-200b in the lung or analyze miR-200b expression
levels during different stages of lung development.
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Figure 21: Effect of TO on Proposed EMT Pathway Markers in the Rabbit Model of CDH. TO increased
expression of miR-33 and MKI67, and decreased expression of Lgl1 in fetal CDH+TO rabbits. The expression of
other Wnt and TGF- signaling markers miR-375, WIF1, Wnt2, BMP4, miR-200b, and PDE5A, were unchanged.

There are several possible explanations for the differences in gene expression results reported
in our study compared to previously reported literature. Firstly, some previously reported studies
include low specimen numbers of 3-4 CDH or CDH+TO fetuses. Small sample sizes could
potentially skew results, while larger samples are likely more realistic in reflecting biological
variance. The Engels paper was also at risk of possible selection bias: 6 CDH+TO RNA samples
were analyzed, but 3 were excluded. Results for two of the samples clustered with the CDH group
and were therefore considered non-responsive to the TO treatment, and one sample was excluded
because it was considered an outlier. Secondly, chemical and surgical models are very different
with respect to CDH creation. Nitrofen induces a diaphragmatic defect early in gestation in
addition to its teratogenic effect on the RA pathway. Conversely, a surgical defect in rabbits is
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created at a similar gestational age and lung development stage to humans. Thus, CDH induction
and prenatal interventions such as TO will have different effects on gene expression [43]. Thirdly,
different species have variable lengths of fetal gestation and stages of lung development [43].
Comparing changes in gene expression at term gestation in multiple species may not coincide with
the same stage of lung development. This could be explored in the future by analyzing gene
expression from lungs at different stages of development in the fetal rabbit and not just at term
gestation. Lastly, gene expression may also vary from species to species, so comparing the same
gene in different species may result in discordant data [43]. There were also several limitations in
our study. The gene expression results were based on mRNA in whole lung tissue. Unfortunately,
the distribution and localization of gene expression within the lung was not analyzed. Differences
have been described in proximal – distal airways, which our study was not able to examine. This
could be explored in the future with techniques such as immunohistochemistry and in situ
hybridization, although it remains difficult to find rabbit primers and antibodies [43,64].
Furthermore, mRNA levels may not correspond to functional protein levels in tissue [88,89].
Therefore, to fully understand the genotype to phenotype expression relationship, protein analysis
should be performed in addition to RT-qPCR assessment of RNA transcripts [88,89].

58

Figure 22: The Effects of CDH and TO on Fetal Rabbit Lung Development. CDH caused lung hypoplasia
demonstrated by low LBWR and high MTBD with no significant difference in lung development markers. TO
reversed lung hypoplasia in CDH fetuses resulting in high LBWR and low MTBD. TO increased expression of miR33 and MKI67 and decreased Lgl1 expression.

In conclusion, the rabbit model of CDH caused pulmonary hypoplasia which was reversed by
TO (Figure 22). TO stimulated early Wnt/-catenin signaling by upregulating miR-33. This
mechanism stimulated lung development as reflected by the upregulation of cell proliferation
marker MKI67. TO likely downregulated Lgl1 expression through a negative feedback loop
following alveolarization at term gestation in CDH fetal rabbits (Figure 21). This research has
deepened our understanding of the effects of CDH and TO on lung development pathways
involved in EMT, and specifically multiple components of the Wnt signaling pathway. We have
established the groundwork for future research that may include exploring gene expression during
different stages of lung development, analyzing the distribution of mRNA within the lung tissue,
determining protein distribution to gain more information on gene expression at the functional
level, and developing prenatal therapy using molecular lung development targets such as miR-33.
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B. Sample Size Calculation
Resource: www.stat.ubc.ca
Based on pilot study data:
mu1: Control MTBD = 5.33
mu2: CDH MTBD = 7.87
Sigma = 2
2-sided test
Alpha = 0.05
Desired power = 0.80
Result: Sample size = 10

Screen Shot of Website Sample Size Calculator:
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C. Correlation Graphs: Supplementary Figures 1 - 9
Control
0

-1

-1

Wnt2 (-ΔCt)

Wnt2 (-ΔCt)

Control
0

-2

-3

-4
0.00

-2

-3

0.01

0.02

0.03

-4

0.04

0

2

4

LBWR

-1.5

-1.5

-2.0

-2.0

-3.0

-3.0
0.00

0.01

0.02

0.03

3

4

5

7

CDH
0

-1

-1

Wnt2 (-ΔCt)

Wnt2 (-ΔCt)

CDH
0

-2

-2

-3
0.01

6

MTBD

LBWR

0.02

0.03

0.04

0

5

10

15

MTBD

LBWR

CDH+TO

CDH+TO

0

0

-1

-1

Wnt2 (-ΔCt)

Wnt2 (-ΔCt)

10

-2.5

-2.5

-2

-2

-3

-3

-4
0.00

8

Sham CDH
-1.0

Wnt2 (-ΔCt)

Wnt2 (-ΔCt)

Sham CDH
-1.0

-3
0.00

6

MTBD

-4
0.02

0.04

LBWR

0.06

0

2

4

6

8

10

MTBD

Supplementary Figure 1: Correlation Graphs of Wnt2 vs. LBWR and Wnt2 vs. MTBD. Wnt 2 expression data
presented as -Ct. Wnt2 vs LBWR – control R2=0.03, p =0.57; sham CDH R2=0.34, p=0.22; CDH R2=0.19, p=0.16;
CDH+TO R2=0.04, p=0.5. Wnt2 vs MTBD – control R2=0.000005, p=0.99; sham CDH R2=0.47, p=0.13; CDH
R2=0.25, p=0.10; CDH+TO R2=0.13, p=0.20.
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Supplementary Figure 2: Correlation Graphs of BMP4 vs LBWR and BMP4 vs MTBD. BMP4 expression data
presented as -Ct. BMP4 vs LBWR – control R2=0.08, p=0.33; sham CDH R2=0.59, p=0.07; CDH R2=0.02,
p=0.64; CDH+TO R2=0.40, p=0.02. BMP4 vs MTBD – control R2=0.02, p=0.60; sham CDH R2=0.85, p=0.01;
CDH R2=0.03, p=0.57; CDH+TO R2=0.25, p=0.07.
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Supplementary Figure 3: Correlation Graphs of Lgl1 vs LBWR and Lgl1 vs MTBD. Lgl1 expression data
presented as -Ct. Lgl1 vs LBWR – control R2=0.02, p=0.63; sham CDH R2=0.41, p=0.17; CDH R2=0.01, p=0.79;
CDH+TO R2=0.28, p=0.05. Lgl1 vs MTBD – control R2=0.0013, p=0.90; sham CDH R2=0.47, p=0.14; CDH
R2=0.02, p=0.64; CDH+TO R2=0.22, p=0.09.
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Supplementary Figure 4: Correlation Graphs of PDE5A vs LBWR and PDE5A vs MTBD. PDE5A expression
data presented as -Ct. PDE5A vs LBWR – control R2=0.02, p=0.61; sham CDH R2=0.38, p=0.20; CDH R2=0.11,
p=0.29; CDH+TO R2=0.30, p=0.04. PDE5A vs MTBD – control R2=0.004, p=0.83; sham CDH R2=0.31, p=0.25;
CDH R2=0.08, p=0.38; CDH+TO R2=0.31, p=0.04.
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Supplementary Figure 5: Correlation Graphs of MKI67 vs LBWR and MKI67 vs MTBD. MKI67 expression
data presented as -Ct. MKI67 vs LBWR – control R2=0.15, p=0.17; sham CDH R2=0.001, p=0.95; CDH R2=0.04,
p=0.54; CDH+TO R2=0.26, p=0.06. MKI67 vs MTBD – control R2=0.06, p=0.40; sham CDH R2=0.004, p=0.91;
CDH R2=0.17, p=0.19; CDH+TO R2=0.0007, p=0.93.
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Supplementary Figure 6: Correlation Graphs of WIF1 vs LBWR and WIF1 vs MTBD. WIF1 expression data
presented as -Ct. WIF1 vs LBWR – control R2=0.16, p=0.16; sham CDH R2=0.58, p=0.08; CDH R2=0.17, p=0.21;
CDH+TO R2=0.18, p=0.13. WIF1 vs MTBD – control R2=0.05, p=0.45; sham CDH R2=0.28, p=0.28; CDH
R2=0.04, p=0.57; CDH+TO R2=0.03, p=0.54.
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Supplementary Figure 7: Correlation Graphs of miR-33 vs LBWR and miR-33 vs MTBD. miR-33 expression
data presented as -Ct. miR-33 vs LBWR – control R2=0.090, p=0.3; sham CDH R2=0.19, p=0.38; CDH R2=0.08,
p=0.37; CDH+TO R2=0.03, p=0.55. miR-33 vs MTBD – control R2=0.0008, p=0.92; sham CDH R2=0.24, p=0.33;
CDH R2=0.08, p=0.38; CDH+TO R2=0.000002, p=0.99.
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Supplementary Figure 8: Correlation Graphs of miR-200b vs LBWR and miR-200b vs MTBD. miR-200b
expression data presented as -Ct. miR-200b vs LBWR – control R2=0.17, p=0.15; sham CDH R2=0.02, p=0.78;
CDH R2=0.25, p=0.1; CDH+TO R2=0.04, p=0.49. miR-200b vs MTBD – control R2=0.00003, p=0.98; sham CDH
R2=0.06, p=0.65; CDH R2=0.25, p=0.1; CDH+TO R2=0.01, p=0.8.
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Supplementary Figure 9: Correlation Graphs of miR-375 vs LBWR and miR-375 vs MTBD. miR-375
expression data presented as -Ct. miR-375 vs LBWR – control R2=0.12, p=0.22; sham CDH R2=0.005, p=0.9;
CDH R2=0.002, p=0.89; CDH+TO R2=0.004, p=0.84. miR-375 vs MTBD – control R2=0.0000008, p=1.00; sham
CDH R2=0.03, p=0.73; CDH R2=0.002, p=0.9; CDH+TO R2=0.001, p=0.9.
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